A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors
Latest Information Update: 29 Jun 2023
At a glance
- Drugs 9MW 3811 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Mabwell (Shanghai) Bioscience
- 29 Jun 2023 New trial record